Portugal's National Medicines Authority (Infarmed) has barred 39 drugs from leaving the country this month, expanding its export suspension list by four medications compared to May as supply pressures mount across therapeutic categories that include cancer treatment, schizophrenia management, and hemorrhagic episodes. The restriction, which took effect on 10 June, represents the latest monthly adjustment to a defensive mechanism designed to keep essential medicines accessible to patients inside Portugal's borders.
Why This Matters:
• Cancer and psychiatric patients face particular vulnerability: the ban now covers oncology drugs and antipsychotics amid existing treatment delays.• Broader supply chain stress: Portugal's wait time for new oncology drugs averages 919 days, placing it among Europe's slowest for access to innovative therapies.• Export curbs will tighten further: the restriction applies to all supply chain participants, including manufacturers and wholesale distributors, effectively locking stock within the national market.
What Drives the Monthly Export Ban
The Infarmed authority publishes this list monthly through a formalized deliberation process—the latest being Deliberation 062/CD/2025. The mechanism targets two categories: drugs that experienced supply disruptions in the prior month with medium or high impact ratings, and those being dispensed under Exceptional Use Authorizations (AUE), a regulatory pathway for medications without standard market approval.
Among the 39 entries on June's roster are morphine, a broad-spectrum antibiotic, glaucoma eye drops, and the aforementioned treatments for bleeding disorders, various cancers, and schizophrenia. The suspension extends to every actor in the pharmaceutical distribution chain, from factory floors to wholesaler warehouses, with one objective: ensure medicines remain in Portugal for domestic patients.
The authority monitors supply conditions daily, tracking shortages, stock-outs, and commercial discontinuations to identify critical scenarios before they escalate. This surveillance feeds into a broader European framework: Portugal participates in a contact network coordinated by the European Medicines Agency (EMA) and the European Commission, operational since April 2019, which shares real-time intelligence on drug availability and disruption across the European Union.
The Structural Roots of Shortage
The shortages driving these export bans reflect a confluence of geopolitical turbulence, cost inflation, and systemic vulnerabilities in pharmaceutical supply chains. While Infarmed has stated Portugal has not yet experienced critical ruptures, the authority acknowledges persistent risk factors that demand constant vigilance.
Conflict in the Middle East has spiked fuel and energy costs, cascading through logistics networks and raising the price of raw materials, from plastics and aluminum to packaging and transport. Europe's dependence on Asian manufacturers for active pharmaceutical ingredients—the therapeutic molecules at the heart of finished drugs—leaves the continent exposed to disruptions thousands of kilometers away.
Domestic economic pressures compound these external shocks. A regulated pricing system in Portugal limits the industry's ability to absorb cost increases, squeezing the economic viability of certain drugs. The extraordinary tax on medicine sales—a relic from the Troika bailout era—further strains profitability, according to the Portuguese Association for Equity in Health Medicines (EQUALMED), which warns this levy can make supplying hospitals and pharmacies economically unworkable.
Across Europe, drug shortages remain a structural and systemic challenge, typically managed reactively rather than prevented. Community pharmacies spend an average of 12 hours per week wrestling with stock-outs, according to sector reports, a burden that translates to delayed treatments and patient anxiety.
Impact on Cancer, Psychiatric, and Hemorrhagic Patients
The inclusion of oncology, schizophrenia, and hemorrhage medications on the export suspension list reflects acute pressure points in Portugal's therapeutic landscape.
Cancer care in Portugal already contends with extraordinary delays: the country's 919-day average wait for access to novel oncology drugs places it far behind European peers. The Portuguese Institute of Oncology (IPO) has resorted to borrowing medicines from other hospital units during shortages, a stopgap measure that underscores the fragility of supply.
For schizophrenia treatment, Infarmed flagged scarcity of quetiapine—used for schizophrenia, depression, and bipolar episodes—in early 2025, advising clinicians to consider alternative therapies and pharmacies to limit dispensing to one month's supply per patient. That drug now appears alongside other antipsychotics on the export ban list.
Medications for hemorrhagic episodes, critical for patients with clotting disorders, also feature prominently, reflecting stock vulnerabilities in a category where alternatives are often limited or require careful clinical substitution.
What This Means for Residents and Healthcare Providers
For patients in Portugal, the export ban is a protective measure that prioritizes domestic need over international commerce. It signals that Infarmed considers these 39 drugs at elevated risk of stock-out and is willing to deploy trade restrictions to prevent it.
However, the ban does not guarantee unlimited availability. It merely prevents existing stock from flowing out of the country. Supply-side disruptions—manufacturing delays, ingredient shortages, or regulatory hold-ups—can still cause gaps on pharmacy shelves and hospital formularies.
Healthcare providers should anticipate tighter inventory management, particularly for the listed drugs. Clinicians may need to discuss alternative therapies with patients if first-line options become scarce, and pharmacists should prepare for more frequent substitution conversations and prior authorization requests.
For expatriates and foreign residents relying on specific medications, the export ban means cross-border refills from Portugal are now impossible for the 39 affected drugs. Patients who split time between Portugal and other jurisdictions should confirm availability in both locations and plan accordingly.
European Coordination and Long-Term Solutions
Portugal's monthly export suspensions occur within a broader European effort to stabilize pharmaceutical supply. The EMA and European Commission have rolled out multiple initiatives targeting the root causes of drug shortages.
The Critical Medicines Act (CMA), which reached provisional agreement in mid-2025, introduces strategic projects with accelerated licensing, joint procurement for critical drugs, and mandatory supply chain mapping to expose vulnerabilities. The legislation encourages international partnerships to diversify sourcing and reduce reliance on single suppliers.
The EU Pharmaceutical Strategy, launched in 2020, pursues a patient-centered, crisis-resilient system with affordable access as a cornerstone. This overarching framework has spawned concrete mechanisms, including the Executive Steering Group on Shortages and Safety of Medicines (MSSG), established by the EMA in March 2022, which coordinates urgent action across member states.
The European Shortage Monitoring Platform (ESMP), operational since early 2025, compels marketing authorization holders to submit supply data on critical medicines, enabling proactive shortage detection. A voluntary solidarity mechanism allows EU and European Economic Area countries to request mutual assistance when critical shortages emerge.
Revision of the EU pharmaceutical legislation, which achieved political consensus in late 2024, establishes reforms to incentivize innovation, improve patient access, prevent shortages, and institutionalize systematic supply chain monitoring. These measures, alongside the CMA, form the legislative backbone of Europe's response to the current availability crisis.
Looking Ahead: Reserves and Resilience
The Portuguese Government plans to establish a strategic reserve of medicines and medical devices in the coming years, a buffer intended to cushion the health system during emergencies. This initiative mirrors broader European recognition that resilience requires not only monitoring and coordination but also physical stockpiles positioned for rapid deployment.
In the interim, the monthly export ban list will continue to shift as Infarmed recalibrates priorities based on evolving stock conditions. Patients, clinicians, and pharmacists should monitor these updates closely, as the composition of the list directly signals which therapeutic areas face the greatest supply stress.
The 39-drug restriction is not a static endpoint but a moving response to a dynamic, fragile supply environment. For now, it stands as Portugal's primary tool to ensure that when medicines are scarce, they stay where they are needed most: within the national health system serving residents and citizens.
